Lantern Pharma To Present Preclinical Data On The Efficacy Of LP-184 For Pancreatic Cancer At The AACR Special Conference For Pancreatic Cancer September 14 4:00pm ET
Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to
Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present positive preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research (AACR) Special Conference for Pancreatic Cancer, Sept 13-16th, 2022, in Boston, MA.
LP-184 is a small molecule drug candidate and next generation acylfulvene that preferentially damages DNA in cancer cells that harbor mutations in DNA damage repair (DDR) genes and that overexpress the enzyme PTGR1. Pancreatic cancer cells are expected to be sensitive to LP-184 treatment as around 25% of these cancers harbor both elevated levels of PTGR1 and mutations in DDR genes.
The AACR poster, which is being presented in collaboration with Igor Astsaturov, M.D., Ph.D. at The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center, shows that LP-184 treatment has potent anti-tumor effects in mouse models of pancreatic cancer that harbor mutations in the DDR genes ATR or BRCA1. After two rounds of LP-184 treatment, the ATR and BRCA1 pancreatic cancer mouse models had tumor growth inhibitions of 140% and 112%, respectively. In these mice, LP-184 treatment was generally well-tolerated and minimal differences were observed in body weight and blood counts relative to treatment control groups.
The AACR presentation will show additional data demonstrating that LP-184 can act synergistically in vitro and in vivo with several standard of care or FDA approved agents, including spironolactone and radiation therapy. These results continue to demonstrate LP-184's potential as a therapeutic agent for pancreatic cancer as a monotherapy or in combination with other approved therapies.
LP-184 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer, malignant gliomas, and ATRT, and was also granted a Rare Pediatric Disease Designation for ATRT. These designations and continued positive preclinical data will help to accelerate LP-184 towards a targeted IND submission in Q1 2023 and Phase 1 clinical trials anticipated to commence in Q2 2023.
Details of the poster presentation are listed below and can be found on the AACR conference website. A full version of the poster will be available on Lantern's website on September 19th, 2022.
Title: LP-184, a tumor site activated small molecule synthetic lethal therapeutic, is synthetically lethal in pancreatic cancers with DNA damage repair defects
Date and Time: September 14, 2022, 4:00pm ET
Poster Number: B033
Presenter: Aditya Kulkarni, Ph.D., Lantern Pharma